• Users Online: 71711
  • Home
  • Print this page
  • Email this page

    Article Cited by others

SYMPOSIUM

The future implications and indications of anti-vascular endothelial growth factor therapy in ophthalmic practice

Hussain Nazimul, Ghanekar Yashoda, Kaur Inderjeet

Year : 2007| Volume: 55| Issue : 6 | Page no: 445-450

   This article has been cited by
 
1 COMPARISON OF VISUAL ACUITY OUTCOME IN PROLIFERATIVE DIABETIC RETINOPATHY(PDR) BETWEEN INTRAVITREAL BEVACIZUMAB AND RANIBIZUMAB INJECTIONS
Kalishankar Das, Shafaque Sahar, Kesha Shah, Athokpam Poireiton
INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH. 2022; : 35
[Pubmed]  [Google Scholar] [DOI]
2 Differences in Vitreous Protein Profiles in Patients With Proliferative Diabetic Retinopathy Before and After Ranibizumab Treatment
Xinping She, Chen Zou, Zhi Zheng
Frontiers in Medicine. 2022; 9
[Pubmed]  [Google Scholar] [DOI]
3 Current intravitreal therapy and ocular hypertension: A review
Aditya Sudhalkar, Alper Bilgic, Shail Vasavada, Laurent Kodjikian, Thibaud Mathis, FransescMarch de Ribot, Thanos Papakostas, Viraj Vasavada, Vaishali Vasavada, Samaresh Srivastava, Deepak Bhojwani, Pooja Ghia, Anand Sudhalkar
Indian Journal of Ophthalmology. 2021; 69(2): 236
[Pubmed]  [Google Scholar] [DOI]
4 The use of thalidomide to treat children with tuberculosis meningitis: A review
Ronald van Toorn, Stefan-Dan Zaharie, James A. Seddon, Martijn van der Kuip, A. Marceline van Furth, Johan F. Schoeman, Regan S. Solomons
Tuberculosis. 2021; 130: 102125
[Pubmed]  [Google Scholar] [DOI]
5 Sustained Intraocular Pressure Rise after the Treat and Extend Regimen at 3 Years: Aflibercept versus Ranibizumab
Alper Bilgic, Laurent Kodjikian, Jay Chhablani, Anand Sudhalkar, Megha Trivedi, Viraj Vasavada, Vaishali Vasavada, Shail Vasavada, Samaresh Srivastava, Deepak Bhojwani, Aditya Sudhalkar
Journal of Ophthalmology. 2020; 2020: 1
[Pubmed]  [Google Scholar] [DOI]
6 A review of anti-VEGF agents for proliferative diabetic retinopathy
P Osaadon,X J Fagan,T Lifshitz,J Levy
Eye. 2014;
[Pubmed]  [Google Scholar] [DOI]
7 Microvascular complications and diabetic retinopathy: recent advances and future implications
Megha Barot,Mitan R Gokulgandhi,Sulabh Patel,Ashim K Mitra
Future Medicinal Chemistry. 2013; 5(3): 301
[Pubmed]  [Google Scholar] [DOI]
8 The pathogenesis of early retinal changes of diabetic retinopathy
G. B. Arden, S. Sivaprasad
Documenta Ophthalmologica. 2012;
[HTML Full text]  [Google Scholar] [DOI]
9 Treatment of proliferative diabetic retinopathy with anti-VEGF agents
Aysha Salam, Raeba Mathew, Sobha Sivaprasad
Acta Ophthalmologica. 2011; : no
[HTML Full text]  [Google Scholar] [DOI]
10 Review of Anti-VEGF Therapy in Proliferative Diabetic Retinopathy
Jardeleza, M.S.R. and Miller, J.W.
. 2009; 24(2): 87-92
[Pubmed]  [Google Scholar]
11 Bevacizumab and ranibizumab on microvascular endothelial cells: A comparative study
Raquel Costa, Ângela Carneiro, Ana Rocha, Ana Pirraco, Manuel Falcão, Luísa Vasques, Raquel Soares
Journal of Cellular Biochemistry. 2009; 108(6): 1410-1417
[Pubmed]  [Google Scholar] [DOI]
12 Effects of hydralazine on ocular blood flow and laser-induced choroidal neovascularization
Jiang, W., Chiou, G.C.Y.
International Journal of Ophthalmology. 2008; 8(12): 2359-2363
[Pubmed]  [Google Scholar]
13 New VEGF antagonists as possible therapeutic agents in vascular disease
Slevin, M., Kumar, P., Wang, Q., Kumar, S., Gaffney, J., Grau-Olivares, M., Krupinski, J.
Expert Opinion on Investigational Drugs. 2008; 17(9): 1301-1314
[Pubmed]  [Google Scholar]
14 New VEGF antagonists as possible therapeutic agents in vascular disease
M Slevin,P Kumar,Quiyu Wang,S Kumar,J Gaffney,M Grau-Olivares,J Krupinski
Expert Opinion on Investigational Drugs. 2008; 17(9): 1301
[Pubmed]  [Google Scholar] [DOI]

 

Read this article